For broad-split groups where the broad antigen was very rare, we excluded the broad antigen and analyzed each child antigen as their own category.
|
|
- Madeleine Williamson
- 6 years ago
- Views:
Transcription
1 Description of categorization of broad and split antigens HLA antigen classifications have evolved over time as assay development has allowed the detection of differences in antigens ( split categories) that were previously undistinguishable ( broad categories). Our study included 21 groups of antigens that were affected by broad categories splitting over time. For broad-split groups where the broad antigen was very rare, we excluded the broad antigen and analyzed each child antigen as their own category. A9 Broad (Splits A23 and A24) A10 Broad (Splits A25, A26, A34, and A66) A19 Broad (Splits A29, A30, A31, A32, A33, and A74) B5 Broad (Splits B51 and B52) B12 Broad (Splits B44 and B45) B15 Broad (Splits B62, B63, and B75) B16 Broad (Splits B38 and B39) B17 Broad (Splits B57 and B58) B21 Broad (Splits B49 and B50) B22 Broad (Splits B55 and B56) B40 Broad (Splits B60 and B61) When one or more split antigens were very rare, we combined the splits with the broad antigen for each group to aggregate the data for analysis. A28 Broad (Splits A68 and A69) B14 Broad (Splits B64 and B65) B70 Broad (Splits B71 and B72) C3 Broad (Splits C9 and C10) There were 6 antigen groups where there appeared to be gradual phase out of the broad categories and phase in of the split categories over time. For these groups, we examined the
2 prevalence trends over time. We excluded the broad categories from analysis, and included the split categories for transplants occurring on or after the year at which there was at least twothirds (67%) of the phase in of the split category had been achieved. DR2 Broad (Splits DR15 and DR16; 1995) DR5 Broad (Splits DR11 and DR12; 1991) DR6 Broad (Splits DR13 and DR14; 1995) DR3 Broad (Splits DR17 and DR18; 1995) DQ1 Broad (Splits DQ5 and DQ6; 1995) DQ3 Broad (Splits DQ7, DQ8, and DQ9; 1995)
3 1 Table S1. Associations between HLA mismatch and diffuse large B-cell lymphoma among kidney transplant recipients (only) Antigen Mismatch number recipients with DLBCL n (%) n (%) recipients without DLBCL SIR IRR a 95% CI P for trend A (25.05) 30,236 (22.79) ( ) (44.10) 56,650 (42.70) ( ) (30.67) 45,196 (34.06) reference B (19.96) 25,213 (19.00) ( ) (44.10) 51,717 (38.98) ( ) (35.75) 55,153 (41.57) reference DR (23.96) 31,841 (24.00) ( ) (46.10) 62,765 (47.31) ( ) (29.22) 37,187 (28.03) reference A+B+DR 0 60 (10.89) 14,423 (10.87) ( ) (6.53) 7,036 (5.30) ( ) 2 71 (12.89) 15,329 (11.55) ( ) (21.78) 27,624 (20.82) ( ) (21.23) 26,616 (20.06) ( ) 5 88 (15.97) 27,336 (20.60) ( ) 6 58 (10.53) 13,749 (10.36) reference SIR=Standardized incidence ratio; IRR=Incidence rate ratio a IRRs were calculated as the ratio of incidence rates between each category of mismatch and the reference mismatch category, and were adjusted for sex, age at transplant, race/ethnicity, year of transplant, transplanted organ, transplant number, panel reactive antibody score, and donor vital status.
4 2 Table S2. Associations between HLA mismatch and early- and late-onset diffuse large B-cell lymphoma among kidney transplant recipients (only) Early-onset DLBCL ( 2 years after transplantation) Late-onset DLBCL (> 2 years after transplantation) Antigen Mismatch number IRR * 95%CI P for trend IRR a 95%CI P for trend A ( ) ( ) ( ) 0.89 ( ) reference 1.00 reference B ( ) ( ) ( ) 0.88 ( ) reference 1.00 reference DR ( ) ( ) reference A+B+DR ( ) ( ) ( ) ( ) ( ) ( ) reference -- DLBCL=Diffuse large B-cell lymphoma; IRR=Incidence rate ratio a IRRs were calculated as the ratio of incidence rates between each category of mismatch and the reference mismatch category, and were adjusted for sex, age at transplant, race/ethnicity, year of transplant, transplanted organ, transplant number, panel reactive antibody score, and donor vital status.
5 3 Table S3. Associations between HLA antigens and diffuse large B-cell lymphoma Antigen recipients with DLBCL n (%) n (%) recipients without DLBCL SIR IRR a 95% CI P value HLA-A A3 232 (25.72) 35,116 (20.50) ( ) A28 + A68 + A (12.75) 20,160 (11.77) ( ) A32 36 (3.99) 8,876 (5.18) ( ) A25 18 (2.00) 4,491 (2.62) ( ) A33 32 (3.55) 10,340 (6.04) ( ) A66 3 (0.33) 1,857 (1.08) ( ) A2 417 (46.23) 78,722 (45.95) ( ) A1 235 (26.05) 37,938 (22.14) ( ) A23 46 (5.10) 12,952 (7.56) ( ) A11 94 (10.42) 17,906 (10.45) ( ) A36 4 (0.44) 2,056 (1.20) ( ) A30 77 (8.54) 17,258 (10.07) ( ) A74 8 (0.89) 3,452 (2.01) ( ) A31 51 (5.65) 9,155 (5.34) ( ) A29 65 (7.21) 11,711 (6.84) ( ) A34 14 (1.55) 4,133 (2.41) ( ) A (17.96) 30,396 (17.74) ( ) A26 58 (6.43) 10,140 (5.92) ( ) HLA-B B38 53 (5.88) 6,680 (3.90) ( ) B58 13 (1.44) 7,405 (4.32) ( ) B (11.09) 14,613 (8.53) ( ) B48 2 (0.22) 2,000 (1.17) ( ) B55 15 (1.66) 4,177 (2.44) ( ) B41 10 (1.11) 3,642 (2.13) ( ) B70 + B71 + B72 37 (4.10) 8,343 (4.87) ( ) B63 7 (0.78) 3,109 (1.81) ( ) B7 195 (21.62) 31,070 (18.13) ( ) B47 1 (0.11) 744 (0.43) ( ) B46 8 (0.89) 946 (0.55) ( ) B57 43 (4.77) 10,685 (6.24) ( ) B42 8 (0.89) 4,603 (2.69) ( ) B51 93 (10.31) 15,441 (9.01) ( ) B75 3 (0.33) 1,380 (0.81) ( ) B52 17 (1.88) 4,743 (2.77) ( ) B39 38 (4.21) 9,166 (5.35) ( ) B (21.06) 34,926 (20.39) ( ) B8 184 (20.40) 29,753 (17.37) ( )
6 4 B49 35 (3.88) 6,678 (3.90) ( ) B13 33 (3.66) 6,396 (3.73) ( ) B78 1 (0.11) 632 (0.37) ( ) B27 64 (7.10) 10,104 (5.90) ( ) B56 11 (1.22) 1,754 (1.02) ( ) B14 + B64 + B65 67 (7.43) 11,692 (6.82) ( ) B45 24 (2.66) 5,880 (3.43) ( ) B50 19 (2.11) 4,090 (2.39) ( ) B (17.74) 31,201 (18.21) ( ) B53 31 (3.44) 9,941 (5.80) ( ) B61 28 (3.10) 6,387 (3.73) ( ) B37 20 (2.22) 3,364 (1.96) ( ) B60 86 (9.53) 14,180 (8.28) ( ) B (11.09) 16,903 (9.87) ( ) B (0.57) HLA-C C8 21 (2.33) 8,035 (4.69) ( ) C12 11 (1.22) 2,245 (1.31) ( ) C3 + C9 + C (13.86) 27,215 (15.88) ( ) C7 251 (27.83) 46,553 (27.17) ( ) C5 84 (9.31) 13,196 (7.70) ( ) C6 70 (7.76) 16,335 (9.53) ( ) C15 5 (0.55) 1,396 (0.81) ( ) C4 146 (16.19) 29,767 (17.37) ( ) C100 3 (0.33) 1,627 (0.95) ( ) C2 58 (6.43) 11,739 (6.85) ( ) C16 6 (0.67) 2,476 (1.45) ( ) C1 41 (4.55) 7,805 (4.56) ( ) C (0.46) C ,656 (0.97) HLA-DQ DQ7 b 98 (15.86) 29,725 (20.88) ( ) DQ8 b 64 (10.36) 15,031 (10.56) ( ) DQ5 b 92 (14.89) 22,526 (15.82) ( ) DQ2 281 (31.15) 56,657 (33.07) ( ) DQ6 b 116 (18.77) 32,607 (22.91) ( ) DQ9 b 19 (3.07) 3,896 (2.74) ( ) DQ4 51 (5.65) 13,461 (7.86) ( ) HLA-DR DR13 b 96 (15.53) 29,321 (20.60) ( ) DR17 b 112 (18.12) 22,562 (15.85) ( ) DR9 20 (2.22) 6,208 (3.62) ( ) DR7 163 (18.07) 33,210 (19.38) ( )
7 5 DR4 294 (32.59) 54,989 (32.10) ( ) DR10 23 (2.55) 4,170 (2.43) ( ) DR1 159 (17.63) 26,250 (15.32) ( ) DR16 b 13 (2.10) 4,327 (3.04) ( ) DR15 b 131 (21.20) 29,482 (20.71) ( ) DR18 b 4 (0.65) 3,093 (2.17) ( ) DR12 b 33 (3.89) 8,098 (4.89) ( ) DR11 b 141 (16.63) 29,680 (17.92) ( ) DR8 73 (8.09) 16,037 (9.36) ( ) DR103 7 (0.78) 1,492 (0.87) ( ) DR14 b 41 (6.63) 9,048 (6.36) ( ) DLBCL=Diffuse large B-cell lymphoma; SIR=Standardized incidence ratio; IRR=Incidence rate ratio a IRRs were calculated as the ratio of incidence rates between each antigen category and all other antigens combined, and were adjusted for sex, age at transplant, race/ethnicity, year of transplant, transplanted organ, and transplant number. b This category includes restricted transplant years reflecting when the split antigen category was in common use (described in supplementary materials).
8 6 Table S4. Associations between HLA antigens and diffuse large B-cell lymphoma among kidney transplant recipients (only) Antigen recipients with DLBCL n (%) n (%) recipients without DLBCL SIR IRR a 95% CI P value HLA-A A28 + A68 + A69 79 (14.34) 16,283 (12.27) ( ) A32 19 (3.45) 6,625 (4.99) ( ) A25 10 (1.81) 3,330 (2.51) ( ) A33 22 (3.99) 8,658 (6.53) ( ) A3 125 (22.69) 26,337 (19.85) ( ) A36 4 (0.73) 1,806 (1.36) ( ) A2 252 (45.74) 60,242 (45.40) ( ) A29 40 (7.26) 8,858 (6.68) ( ) A34 12 (2.18) 3,593 (2.71) ( ) A23 32 (5.81) 10,694 (8.06) ( ) A66 3 (0.54) 1,528 (1.15) ( ) A26 36 (6.53) 7,890 (5.95) ( ) A11 68 (12.34) 14,104 (10.63) ( ) A1 131 (23.77) 27,743 (20.91) ( ) A74 7 (1.27) 2,953 (2.23) ( ) A (18.33) 23,647 (17.82) ( ) A31 30 (5.44) 7,304 (5.50) ( ) A30 46 (8.35) 14,054 (10.59) ( ) HLA-B B38 36 (6.53) 5,300 (3.99) ( ) B58 8 (1.45) 6,209 (4.68) ( ) B46 8 (1.45) 852 (0.64) ( ) B41 5 (0.91) 2,854 (2.15) ( ) B63 3 (0.54) 2,558 (1.93) ( ) B57 24 (4.36) 8,368 (6.31) ( ) B55 8 (1.45) 3,191 (2.41) ( ) B18 60 (10.89) 10,954 (8.26) ( ) B48 2 (0.36) 1,795 (1.35) ( ) B7 117 (21.23) 23,659 (17.83) ( ) B70 + B71 + B72 26 (4.72) 7,024 (5.29) ( ) B75 2 (0.36) 1,272 (0.96) ( ) B49 25 (4.54) 5,300 (3.99) ( ) B52 10 (1.81) 3,957 (2.98) ( ) B56 9 (1.63) 1,368 (1.03) ( ) B14 + B64 + B65 43 (7.80) 9,037 (6.81) ( ) B42 7 (1.27) 4,027 (3.04) ( ) B47 1 (0.18) 514 (0.39) ( ) B8 107 (19.42) 21,284 (16.04) ( ) B62 53 (9.62) 12,366 (9.32) ( )
9 7 B60 46 (8.35) 10,565 (7.96) ( ) B50 10 (1.81) 3,141 (2.37) ( ) B27 37 (6.72) 7,535 (5.68) ( ) B39 24 (4.36) 7,288 (5.49) ( ) B (19.42) 24,820 (18.71) ( ) B45 13 (2.36) 4,855 (3.66) ( ) B (21.05) 26,247 (19.78) ( ) B37 12 (2.18) 2,524 (1.90) ( ) B61 19 (3.45) 5,313 (4.00) ( ) B51 52 (9.44) 12,043 (9.08) ( ) B13 22 (3.99) 4,861 (3.66) ( ) B53 24 (4.36) 8,563 (6.45) ( ) B (0.42) B (0.64) HLA-C C12 8 (1.45) 1,650 (1.24) ( ) C7 155 (28.13) 35,420 (26.70) ( ) C3 + C9 + C10 74 (13.43) 20,654 (15.57) ( ) C8 18 (3.27) 6,463 (4.87) ( ) C16 1 (0.18) 1,859 (1.40) ( ) C100 1 (0.18) 1,430 (1.08) ( ) C15 1 (0.18) 1,064 (0.80) ( ) C2 39 (7.08) 9,251 (6.97) ( ) C6 45 (8.17) 12,595 (9.49) ( ) C5 44 (7.99) 9,614 (7.25) ( ) C4 91 (16.52) 24,159 (18.21) ( ) C1 29 (5.26) 6,206 (4.68) ( ) C (0.45) C ,348 (1.02) HLA-DQ DQ7 b 63 (16.41) 23,989 (21.69) ( ) DQ5 b 60 (15.63) 17,705 (16.01) ( ) DQ8 b 38 (9.90) 11,047 (9.99) ( ) DQ9 b 11 (2.86) 2,969 (2.68) ( ) DQ2 169 (30.67) 42,501 (32.03) ( ) DQ4 34 (6.17) 11,184 (8.43) ( ) DQ6 b 78 (20.31) 26,114 (23.61) ( ) HLA-DR DR13 b 58 (15.10) 23,247 (21.02) ( ) DR15 b 91 (23.70) 23,720 (21.45) ( ) DR7 99 (17.97) 25,509 (19.23) ( ) DR17 b 61 (15.89) 16,262 (14.71) ( ) DR1 94 (17.06) 19,828 (14.94) ( ) DR10 15 (2.72) 3,441 (2.59) ( ) DR18 4 (1.04) 2,695 (2.44) ( ) DR12 b 24 (4.58) 6,809 (5.31) ( )
10 8 DR16 b 9 (2.34) 3,428 (3.10) ( ) DR4 172 (31.22) 40,623 (30.62) ( ) DR14 b 26 (6.77) 7,525 (6.80) ( ) DR9 17 (3.09) 4,931 (3.72) ( ) DR11 90 (17.18) 23,815 (18.57) ( ) DR8 46 (8.35) 13,176 (9.93) ( ) DR103 4 (0.73) 1,153 (0.87) ( ) DLBCL=Diffuse large B-cell lymphoma; SIR=Standardized incidence ratio; IRR=Incidence rate ratio a IRRs were calculated as the ratio of incidence rates between each antigen category and all other antigens combined, and were adjusted for sex, age at transplant, race/ethnicity, year of transplant, transplanted organ, transplant number, panel reactive antibody score, and donor vital status. b This category includes restricted transplant years reflecting when the split antigen category was in common use (described in supplementary materials).
OPTN/UNOS Policy Notice Review of HLA Tables (2016)
Review of HLA Tables (2016) Sponsoring Committee: Policy/Bylaws Affected: Histocompatibility Policy 4.10 (Reference Tables of HLA Antigen Values and Split Equivalences) Public Comment: July 31, 2017 October
More informationMATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH
MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH TEJASWINI M. DHAWALE, M.D. HEME FELLOWS CONFERENCE NOVEMBER 08, 2013 CASE PRESENTATION 51 yo M with history of MDS (unilinear
More information6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD?
6/19/212 KPD Webinar Series: Part 3 Demystifying the OPTN Kidney Paired Donation Pilot Program Unacceptable HLA antigens: The key to finding a compatible donor for your patient M. Sue Leffell, Ph.D. J.
More informationThe MHC and Transplantation Brendan Clark. Transplant Immunology, St James s University Hospital, Leeds, UK
The MHC and Transplantation Brendan Clark Transplant Immunology, St James s University Hospital, Leeds, UK Blood Groups Immunofluorescent staining has revealed blood group substance in the cell membranes
More informationRenal Transplantation: Allocation challenges and changes. Renal Transplantation. The Numbers 1/13/2014
Renal Transplantation: Allocation challenges and changes Mark R. Wakefield, M.D., F.A.C.S. Associate Professor of Surgery/Urology Director Renal Transplantation Renal Transplantation Objectives: Understand
More informationThe Kidney Allocation System Changed in a Substantive Way on December 5, Your Patients Have Been, and Will Be, Affected by These Changes
The Kidney Allocation System Changed in a Substantive Way on December 5, 2014 Your Patients Have Been, and Will Be, Affected by These Changes 1 The New Kidney Allocation System Terms of Importance Pediatric
More informationBasel - 6 September J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva
Basel - 6 eptember 2012 J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva Outline the HLA system is (a) complex anti-hla immunisation and alloreactivity
More informationThe Acceptable Mismatch program of Eurotransplant.
The Acceptable Mismatch program of Eurotransplant. Frans Claas Leiden University Medical Center Eurotransplant Reference Laboratory Leiden, the Netherlands. Hinterzarten, December 7, 2013 Main problem
More informationChapter 10. Histocompatibility Testing
Chapter 10 Histocompatibility Testing Chapter 10 Histocompatibility Testing Table of Contents 10.1 General... 3 10.1.1 Registration of renal transplant patients...3 10.1.2 Material for histocompatibility
More informationThe new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials
The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials Carmen Lefaucheur 1 2 Banff 2015: Integration of HLA-Ab for improving
More informationDebate: HLA matching matters in children
Annual Congress 2018 14 th to 16 th March, the Brighton Centre, Brighton Debate: HLA matching matters in children Presenting the case for - Dr Jon Jin (JJ) Kim, Nottingham Richard & Ronald Herrick 23 Dec
More informationTable S1. Clinical outcomes of the acceptable mismatch allocation model.
Table S1. Clinical outcomes of the acceptable mismatch allocation model. Recipient Age PRA Waiting Time (months) HLA mismatch (A/B/DR) HLAMatchmaker acceptable mismatch (years) (%) Actual Simulation Change
More informationUpdate to the Human Leukocyte Antigens (HLA) Equivalency Tables
Update to the Human Leukocyte s (HLA) Equivalency Tables Sponsoring Committee: Histocompatibility Policy/Bylaws Affected: Policy 2.11.A: Required Information for Deceased Kidney Donors, Policy 2.11.B:
More informationThree Sides to Allocation. ECD Extended Criteria Donor
Kidney Allocation- Optimal Use of Deceased Donors The New US System..and impact on wait list management Three Sides to Allocation Justice Peter G Stock MD, PhD Utility Efficiency Standard Criteria Donor
More informationEpitope matching in solid organ transplantation: T-cell epitopes
Epitope matching in solid organ transplantation: T-cell epitopes Eric Spierings (e.spierings@umcutrecht.nl) Laboratory for Translational Immunology, UMC Utrecht conflict of interest: the UMCU has filed
More informationHighly Sensitized Patient Registry: Update and Successes
Highly Sensitized Patient Registry: Update and Successes Dr. Olwyn Johnston Medical Director Kidney and Pancreas Transplant Program Vancouver General Hospital Conflict of Interest Transplant Nephrologist
More informationPatient Education Transplant Services. Glossary of Terms. For a kidney/pancreas transplant
Patient Education Glossary of Terms For a kidney/pancreas transplant Glossary of Terms Page 18-2 Antibody A protein substance made by the body s immune system in response to a foreign substance. Antibodies
More informationUpdate on Kidney Allocation
Update on Kidney Allocation 23rd Annual Conference Association for Multicultural Affairs in Transplantation Silas P. Norman, M.D., M.P.H. Associate Professor Division of Nephrology September 23, 2015 Disclosures
More informationT cell manipulation of the graft: Yes
T cell manipulation of the graft: Yes J.H. Frederik Falkenburg Department of Hematology L M U C Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for non-malignant disorders: no need for anti-tumor
More informationChapter 10. Histocompatibility Testing
Chapter 10 Histocompatibility Testing Change record Date Author Version Change reference 08-03-2013 J. de Boer 2.0 Textual Adjustments 13-09-2012 C.M. Tieken 1.1 Text added page 2 10-03-2012 I. Doxiadis
More informationU.S. changes in Kidney Allocation
U.S. changes in Kidney Allocation Match kidneys with longest survival to patients with longest survival No parallel matching for kidneys with lower survival potential Decrease discard of kidneys with lower
More informationManagement of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale
Management of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale Pooled Platelets (Buffy Coat Derived) Adult dose from 4 ABO-identical donors
More informationSamples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationTransplant Update New Kidney Allocation System Transplant Referral Strategies. Antonia Harford, MD University of New Mexico
Transplant Update New Kidney Allocation System Transplant Referral Strategies Antonia Harford, MD University of New Mexico Financial Disclosures Doctor Harford has received financial support for dialysis
More informationThe New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health
The New Kidney Allocation System: What You Need to Know Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health ~6% of patients die each year on the deceased donor waiting
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationRole of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT
Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,
More informationSamples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationSamples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationPilot on inclusion of a case report in the external proficiency testing program
Pilot on inclusion of a case report in the external proficiency testing program Sebastiaan Heidt Eurotransplant Reference Laboratory ET EXTRA MURAL MEETING 2016 Background At the extramural meeting 2015
More informationShould Pediatric Patients Wait for HLA-DR-Matched Renal Transplants?
American Journal of Transplantation 2008; 8: 2056 2061 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant
More informationCOMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS
COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS A COMPARISON OF THE SURVIVAL OF SHIPPED AND LOCALLY TRANSPLANTED CADAVERIC RENAL ALLOGRAFTS KEVIN C. MANGE, M.D.,
More informationThe New Kidney Allocation System: What You Need to Know. Quality Insights Renal Network 3 Annual Meeting October 2, 2014
The New Kidney Allocation System: What You Need to Know Quality Insights Renal Network 3 Annual Meeting October 2, 2014 Pre Dialysis Era Dialysis Status in USA 500,000 patients on dialysis in 2013 100,000
More informationSupplemental Table 1 Multivariate analysis of neutrophil and platelet
Transplant using vs. HLA 1-AG mismatched RD Supplemental Table 1 Multivariate analysis of neutrophil and platelet engraftment Variable Neutrophil engraftment* Platelet engraftment HR (95% CI) P value HR
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationThe Human Major Histocompatibility Complex
The Human Major Histocompatibility Complex 1 Location and Organization of the HLA Complex on Chromosome 6 NEJM 343(10):702-9 2 Inheritance of the HLA Complex Haplotype Inheritance (Family Study) 3 Structure
More informationTitle: SECTION 7.0 NZBMDR STANDARDS PROCESS FOR DONOR IDENTIFICATION
Title: SECTION 7.0 NZBMDR STANDARDS PROCESS FOR DONOR IDENTIFICATION Authorised by: Executive Officer Contributing Authors: ABMDR Scientific Expert Advisory Committee Sally Gordon Dr Hilary Blacklock Raewyn
More informationHLA Selected Platelets
HLA Selected Platelets Dr PhD Clinical Scientist Department of Histocompatibility & Immunogenetics NHS Blood and Transplant Colindale Poor increment (
More informationlnhs BLOOD AND TRANSPLANT RESEARCH, INNOVATION AND NOVEL TECHNOLOGIES ADVISORY GROUP DCD HEART ACTIVITY
lnhs BLOOD AND TRANSPLANT RESEARCH, INNOVATION AND NOVEL TECHNOLOGIES ADVISORY GROUP INTRODUCTION DCD HEART ACTIVITY 1 DCD heart retrieval began in February 2015 for a 15 month initial evaluation period
More informationHistocompatibility. HLA Serologic Typing (Class I/II) ABO, HLAS, HLAS Surveys & Anatomic Pathology Education Programs
www.cap.org Histocompatibility Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS). HLA Serologic Typing (Class I/II) ABO, HLAS,
More informationThe New Kidney Allocation Policy: Implications for Your Patients and Your Practice
The New Kidney Allocation Policy: Implications for Your Patients and Your Practice Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Explain
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationMed A form: discussion forum
Copyright Statement As a registered E-materials Service user of the EBMT Annual Meeting in Marseille March 26-29th 2017, you have been granted permission to access a copy of the presentation in the following
More informationVascular Remodelling in Pancreas Transplantation
Vascular Remodelling in Pancreas Transplantation Prof Steve White Consultant HPB/Transplant Surgeon The Freeman Hospital Newcastle President Elect EPITA European Pancreas Transplants Pancreas Transplants
More informationSupplementary Online Content
Supplementary Online Content Acuna SA, Fernandes KA, Daly C, et al. Cancer mortality among recipients of solidorgan transplantation in Ontario, Canada. JAMA Oncol. Published online January 7, 2016. doi:10.1001/jamaoncol.2015.5137
More informationKidney, Pancreas and Liver Allocation and Distribution
American Journal of Transplantation 2012; 12: 3191 3212 Wiley Periodicals Inc. Special Article C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
More informationFounded 1969 by the Nordic Council of Ministers
Founded 1969 by the Nordic Council of Ministers Slideshow 217 Scandiatransplant activities Slide presentation of Scandiatransplant activities 217 Presentation, purpose, awards and office Slide 3 Overall
More informationNHS BLOOD AND TRANSPLANT KIDNEY OFFERING SCHEME WORKING GROUP ENDORSEMENT OF A NEW NATIONAL KIDNEY OFFERING SCHEME
NHS BLOOD AND TRANSPLANT KIDNEY OFFERING SCHEME WORKING GROUP ENDORSEMENT OF A NEW NATIONAL KIDNEY OFFERING SCHEME INTRODUCTION 1 Three working groups were established to consider whether changes were
More informationLONG TERM OBSERVATION AFTER CULTURED HUMAN PARATHYROID CELLS ALLOTRANSPLANTATION WITHOUT IMMUNOSUPPRESSION
LONG TERM OBSERVATION AFTER CULTURED HUMAN PARATHYROID CELLS ALLOTRANSPLANTATION WITHOUT IMMUNOSUPPRESSION Nawrot I, Tołłoczko T, Szmidt J, Woźniewicz B, Migaj M, Górski A, Sawicki A, Zawitkowska T, Pietrasik
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationDiagnosis and Management of Acute and Chronic Humoral Rejection. Lars Pape
Diagnosis and Management of Acute and Chronic Humoral Rejection Lars Pape Immunosuppression Acute rejection Chronic rejection Side effects Infections Nephrotoxicity Adult population Nearly all late rejection-related
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationKidney Allocation- Will it ever be fair? Peter G Stock MD, PhD UCSF Department of Surgery. Would you accept this offer?
Kidney Allocation- Will it ever be fair? Peter G Stock MD, PhD UCSF Department of Surgery Question 1: A 19 y/o deceased donor kidney (O mismatch) from NYC is allocated to a 72 y/o highly sensitized caucasian
More informationAutoimmunity & Transplantation. Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:
Autoimmunity & Transplantation Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Learning Objectives By the end of this lecture you will be able to: 1 Recognize
More informationImpact of HLA Mismatch at First Kidney Transplant on Lifetime With Graft Function in Young Recipients
American Journal of Transplantation 2014; 14: 876 885 Wiley Periodicals Inc. C Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12643
More informationDonation & Transplantation Interprovincial Programs Report
Donation & Transplantation Interprovincial Programs Report 29-214 Donation & Transplantation Interprovincial Programs Report 9-214 TERMINOLOGY & USE OF DATA A glossary of terms can be found in Appendix
More informationHUMAN LEUCOCYTE ANTIGEN (HLA) CLASS I AND II FREQUENCIES IN SELECTED GROUPS IN LEBANON
Journal Scientifique Libanais, Vol. 1, No. 1, 2000 119 HUMAN LEUCOCYTE ANTIGEN (HLA) CLASS I AND II FREQUENCIES IN SELECTED GROUPS IN LEBANON Alexander M. Abdelnoor, May Abdelnoor, Walid Heneine, Firas
More information25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex
Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD
More informationThe New Kidney Allocation System (KAS) Frequently Asked Questions
The New Kidney Allocation System (KAS) Frequently Asked Questions Contents General: The Need for the New System and Key Implementation Details... 4 Why was the newly revised KAS necessary?... 4 What were
More informationCD25-PE (BD Biosciences) and labeled with anti-pe-microbeads (Miltenyi Biotec) for depletion of CD25 +
Supplements Supplemental Materials and Methods Depletion of CD25 + T-cells from PBMC. Fresh or HD precultured PBMC were stained with the conjugate CD25-PE (BD Biosciences) and labeled with anti-pe-microbeads
More informationTransplantation. Immunology Unit College of Medicine King Saud University
Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the
More informationManagement of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
More informationEvaluation of Two New Antibody Detection Techniques in Kidney Transplantation. Doctoral Thesis. Dr. Petra Gombos
Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation Doctoral Thesis Dr. Petra Gombos Semmelweis University Doctoral School of Pathology Supervisor: Dr. Róbert Langer, Ph.D. Consultant:
More informationNational Transplant Guidelines
National Transplant Guidelines Quo Vadis? Scott Campbell, Princess Alexandra Hospital, Brisbane. Quo Vadis Whither goest thou? Where the F#$% do we go next? Overview WAITING LIST ELIGIBILITY ALLOCATION
More informationObjectives 3/6/2017. Impact of Non-HLA Antibodies in Lung Transplantation
Impact of Non-HLA Antibodies in Lung Transplantation Nancy L. Reinsmoen, Ph.D., D(ABHI) Director, HLA and Immunogenetics Laboratory (Retired) Cedars Sinai Medical Center Los Angeles, CA Nancy L. Reinsmoen,
More informationChapter 7. Australian Waiting List. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015
Chapter 7 Australian Waiting List 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Stock and Flow The waiting list data reported here are derived from the Australian National Organ Matching System
More informationWorkshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan
Workshop I: Patient Selection Current indication for HCT in adults Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan Factors to Take into Account with Recommending HCT Patient & disease factors
More informationRobert B. Colvin, M.D. Department of Pathology Massachusetts General Hospital Harvard Medical School
Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Robert B. Colvin Transplantation: Friendly organs in a hostile environment Robert B. Colvin,
More informationCancer in kidney transplant recipients: epidemiology and prevention
BTS 2018, Brighton Cancer in kidney transplant recipients: epidemiology and prevention Adnan Sharif Queen Elizabeth Hospital Birmingham Outline 1. The burden of cancer after kidney transplantation 2. Epidemiology
More informationPancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry
American Journal of Transplantation 2016; 16: 688 693 Wiley Periodicals Inc. Brief Communication Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
More informationVirtual Crossmatch in Kidney Transplantation
Virtual Crossmatch in Kidney Transplantation Shiva Samavat Associate Professor of Nephrology Labbafinejad Hospital SBMU 2018.11.21 All transplant candidates are screened to determine the degree of humoral
More informationThe Use of HLA /HPA Selected Platelets
The Use of HLA /HPA Selected Platelets Dr Colin Brown PhD FRCPath. Consultant Clinical Scientist Histocompatibility and Immunogenetics HLA and Transfusion Human Leucocyte Antigens HLA Human Platelet Antigens
More informationWhy so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation
Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation Stephen J Tomlanovich MD Objectives of this Talk Define the sensitized patient Describe the scope of the problem for a
More informationFAIRNESS/EQUITY UTILITY/EFFICACY EFFICIENCY. The new kidney allocation system (KAS) what has it done? 9/26/2018. Disclosures
The new kidney allocation system (KAS) what has it done? Disclosures No financial disclosure Ryutaro Hirose, MD Professor in Clinical Surgery University of California San Francisco Objectives Describe
More informationA Guide to Better Living
Transplantation What Is a Kidney Transplant? Kidney transplantation is placing a kidney from one person (donor) into a patient with kidney failure (recipient). This is done by surgery where the donated
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Gragert L, Eapen M, Williams E, et al. HLA match likelihoods
More informationUEMS & EBS: DIVISION OF TRANSPLANT SURGERY
CURRICULUM AND SYLLABUS TRANSPLANTATION Module 1: Multi-organ retrieval Ability to evaluate donor suitability Ability to retrieve abdominal organs for transplantation Evaluation of donor/ organs suitability
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationCorneal transplantation: HLA and age
L Aquila, 24 novembre 2012 Corneal transplantation: HLA and age Federico Genzano Besso*, Paola Magistroni, Piera Santoro*, Silvano Battaglio*, Raffaella Giacometti, Morteza Mansouri and Antonio Amoroso
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationDisclosures. Investigator-initiated study funded by Astellas
Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development
More informationTransplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation
Transplant Nephrology Update: Focus on Outcomes and Increasing Access to Transplantation Titte R Srinivas, MD, FAST Medical Director, Kidney and Pancreas Transplant Programs Objectives: Describe trends
More informationCarol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT
Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT History Why is blood transfusion involved? What tests are performed in blood transfusion and why? What does a protocol look
More informationCurrent strategies to kidney allocation
Current strategies to kidney allocation Dr Marie Alice Macher Dr Christian Jacquelinet Emilie Savoye Dr Corinne Antoine Direction Prélèvement Greffe organes - tissus From organ sharing to organ allocation
More informationSummary of Significant Changes. Policy
This Policy replaces POL186/2 Copy Number Effective 01/04/14 Summary of Significant Changes Clarification of policy approval process Paragraph 2.2.1 Clarification of Kidney Fast Track Scheme offering criteria
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationThe Practical Application of Statistics: Reading papers and interpreting clinical studies...
The Practical Application of Statistics: Reading papers and interpreting clinical studies... Richard Szydlo Imperial College / Hammersmith Hospital, London Karlskirche Evaluating new treatments
More informationOrgan transplantation in Bulgaria
Cell Tissue Banking (28) 9:337 342 DOI 1.17/s1561-7-935-2 Organ transplantation in Bulgaria Elissaveta Naumova Æ Petar Panchev Æ Pencho J. Simeonov Æ Anastassia Mihaylova Æ Kalina Penkova Æ Petia Boneva
More informationSevere Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia
Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia Liat Shragian Alon, MD Rabin Medical Center, ISRAEL #EBMT15 www.ebmt.org Patient: 25-year-old male No prior medical history
More informationQuantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b
Quantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b a John Hopkins University, Immunogenetics Laboratory, Baltimore, Maryland and b Cedars-Sinai
More informationWhat Happens on Call?? June 02, 2016
What Happens on Call?? June 02, 2016 MSI Donor Registry High Status Organ Offers Referrals from NS NB & NL Donors National Open Organ Offers 4S Heart Offers General Inquires HSP Kidney Offers Potential
More informationIntroduction to Hematopoietic Stem Cell Transplantation
Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up
More informationIMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar
IMMUNOBIOLOGY OF TRANSPLANTATION Wasim Dar Immunobiology of Transplantation Overview Transplantation: A complex immunologic process Contributions Innate Immunity Adaptive immunity T Cells B Cells HLA Consequences
More informationDonor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients Stanley C. Jordan, MD Director, Division of Nephrology Medical Director, Kidney Transplant Program Medical
More informationPaired Donation. Andrew Bradley Rachel Johnson Joanne Allen Susan V Fuggle. Cambridge University NHS Hospitals NHS Foundation trust
Paired Donation Andrew Bradley Rachel Johnson Joanne Allen Susan V Fuggle Cambridge University NHS Hospitals NHS Foundation trust Showing a preference 1860 John Calcott Horsley UK Living Donor kidney transplant
More informationNew Zealand Kidney Allocation Scheme
New Zealand Kidney Allocation Scheme The New Zealand Kidney Allocation Scheme (NZKAS) has been developed to ensure that kidney allocation in NZ is performed on an equitable, accountable and transparent
More informationPredicting HLA Class II Alloantigen Immunogenicity From the Number and Physiochemical Properties of Amino Acid Polymorphisms
CLINICAL AND TRANSLATIONAL RESEARCH Predicting HLA Class II Alloantigen Immunogenicity From the Number and Physiochemical Properties of Amino Acid Polymorphisms Vasilis Kosmoliaptsis, 1,2,6 Linda D. Sharples,
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More information